Mitomycin (Mitosol) — Clinical FAQs

Q: Is Mitomycin safe during pregnancy?

Mitomycin pregnancy safety: Category D — mitomycin is mutagenic, teratogenic, and clastogenic in animal studies. It should be considered potentially teratogenic and harmful to the developing fetus in humans. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the last dose. Male patients should use effective contraception during treatment and for at least 3 months after the last dose. Advise against breastfeeding during treatment.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Question 1

What is Mitomycin FDA-approved to treat?

Accepted Answer

Mitomycin is FDA-approved for the following oncology indications: 1. Disseminated adenocarcinoma of the stomach and pancreas: palliative treatment in combination with other chemotherapy agents (IV formulation) 2. Anal canal carcinoma: in combination with 5-fluorouracil and radiation therapy (Nigro chemoradiation regimen; IV formulation) 3. Low-grade upper tract urothelial carcinoma (LGUTUC): endoscopic treatment of adult patients following complete endoscopic resection (Jelmyto — mitomycin gel, pyelocalyceal instillation) 4. Non-muscle-invasive bladder cancer (NMIBC): intravesical instillation as adjunct to transurethral resection (TUR) in select patients (Mitosol / generic intravesical formulation).

Question 2

How does Mitomycin work (mechanism of action)?

Accepted Answer

Mitomycin is a bioreductive alkylating agent derived from Streptomyces caespitosus. It is a prodrug that undergoes enzymatic reductive activation by intracellular reductases (primarily DT-diaphorase and cytochrome P450 reductase) under hypoxic conditions to generate highly reactive alkylating intermediates, including semiquinone radicals and aziridinium ions. These activated species form covalent interstrand and intrastrand DNA cross-links, preferentially at N2-guanine positions in CpG sequences, irreversibly inhibiting DNA replication and transcription and triggering apoptosis. The reductive activation is enhanced in the characteristically hypoxic tumor microenvironment, providing a degree of tumor selectivity. Cross-linking of DNA strands prevents strand separation during replication, making mitomycin particularly active against cells that are relatively resistant to conventional cell-cycle-specific agents, and additionally generates reactive oxygen species (ROS) that contribute to oxidative DNA damage.

Question 3

How is Mitomycin administered?

Accepted Answer

Mitomycin is administered Intravenous (IV) or Intravesical. IV administration: 20 mg/m² IV bolus or short infusion (over 15–30 minutes) every 6–8 weeks as a single agent; alternatively 10 mg/m² every 6–8 weeks in combination regimens.

Question 4

What are the most common side effects of Mitomycin?

Accepted Answer

The most commonly reported side effects of Mitomycin (≥10% incidence) include: Myelosuppression: thrombocytopenia and leukopenia (≥64%; delayed, nadir weeks 4–6), Nausea and vomiting (≥14%; moderately emetogenic IV), Anorexia and fatigue (≥14%), Stomatitis / mucositis (≥14%; IV administration), Alopecia (≥14%; IV administration) and others (9 total). Consult your oncologist for complete prescribing information.

Question 5

Does Mitomycin have a black box warning?

Accepted Answer

Yes. Mitomycin carries FDA black box warning(s) regarding: 1. Myelosuppression (IV): Bone marrow suppression is a major dose-limiting toxicity of mitomycin. Suppression is delayed and cumulative — the CBC nadir typically occurs 4–6 weeks after each dose. Thrombocytopenia and leukopenia are the most pronounced manifestations. Obtain CBC with differential and platelet count prior to each course of therapy; do not administer if platelet count <75,000/mm³ or WBC <3,000/mm³. CBC monitoring must continue for at least 8 weeks after each course. 2. Hemolytic Uremic Syndrome (HUS): A syndrome of microangiopathic hemolytic anemia (Coombs-negative), thrombocytopenia, and irreversible renal failure has been reported in patients receiving mitomycin. HUS can occur at any time during therapy and is often fatal. The syndrome may be precipitated or exacerbated by blood transfusions; avoid transfusions if HUS is suspected. Permanently discontinue mitomycin if HUS develops.

Question 6

Is Mitomycin safe during pregnancy?

Accepted Answer

Mitomycin pregnancy safety: Category D — mitomycin is mutagenic, teratogenic, and clastogenic in animal studies. It should be considered potentially teratogenic and harmful to the developing fetus in humans. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the last dose. Male patients should use effective contraception during treatment and for at least 3 months after the last dose. Advise against breastfeeding during treatment.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Mitomycin — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms